EUCTR2004-002502-29-IT进行中（未招募）不适用
A six month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six month open label extension) to assess the safety and efficacy of 700microg and 350microg dexamehtasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion
ALLERGA0 个研究点开始时间: 2005年6月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Oedema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.EUCTR2004-002502-29-HUAllergan Limited650
进行中（未招募）
不适用
A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Oedema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.Macular Oedema due to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)EUCTR2004-002496-17-CZAllergan Limited550
进行中（未招募）
不适用
A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Oedema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.Macular Oedema due to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)EUCTR2004-002496-17-DEAllergan Limited550
进行中（未招募）
不适用
A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.EUCTR2004-002496-17-ATAllergan Limited550
进行中（未招募）
1 期
A Six-Month Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion.Macular edema due to Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)EUCTR2004-002502-29-GBAllergan Limited550